Prevalence, Clinical Features and Risk Factors of Cirrhotic Cardiomyopathy Assessed by Two-dimensional Speckle Tracking Imaging

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-01

Study Completion Date

2022-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the prevalence of cirrhotic cardiomyopathy in patients with cirrhosis, and to analyze the correlation between the severity of cirrhosis and cardiac dysfunction. To investigate the risk factors for cirrhotic cardiomyopathy, and raise clinicians' awareness of cirrhotic cardiomyopathy, early assessment and intervention to improve long-term outcomes in patients with cirrhosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Myocardial Fibrosis and Inflammation in Liver Cirrhosis

NCT05047029

Cirrhosis, Liver Cardiomyopathies Portal Hypertension

COMPLETED

Prevelance of Fragmented QRS Complex and Prolonged QT Interval in Cirrhotic Patients

NCT03158701

Liver Cirrhosis

UNKNOWN

Subclinical Cardiovascular Changes in NAFLD Patient (Predictive Value of Speckle Tracking Echocardiography )

NCT05790057

Liver Steatoses

UNKNOWN

A Model Based on Computed Tomography Imaging Parameters to Predict Poor Survival in Patients With Liver Cirrhosis

NCT05208736

Liver Cirrhosis

UNKNOWN

Evaluation of Hepatic Fibrosis on Multiparametric MRI

NCT03085342

Cirrhosis Hepatitis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Liver cirrhosis is the terminal stage of the development of chronic liver disease caused by various reasons, and it is often accompanied by multiple complications. Late cirrhosis is often accompanied by obvious changes in liver and systemic hemodynamics. Patients with liver cirrhosis are in a highly dynamic cycle Status: lower arterial blood pressure, increased heart rate, increased cardiac output, peripheral vascular resistance, which often lead to changes in myocardial structure and function, called cirrhotic cardiomyopathy. Cirrhotic cardiomyopathy (CCM) is defined as cardiac dysfunction in patients with end-stage liver disease in the absence of prior heart disease. The true burden of CCM among patients with ESLD is currently unknown. Prior studies evaluated CCM prevalence and estimated it to be approximately 50%, however, this estimate was based on the old criteria. In 2020, the Cirrhotic Cardiomyopathy Association updated the diagnostic criteria for cirrhotic cardiomyopathy. At present, the true prevalence of cirrhotic cardiomyopathy still needs to be reassessed. In addition, studies on the risk factors for cirrhotic cardiomyopathy are rare. Based on the above research background, carry out this research.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhosis Cirrhotic Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with liver cirrhosis

cirrhosis based on either clinical/radiological parameters or liver histology

Not

Intervention Type OTHER

Not

control group

Healthy ubjects without known heart disease

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Not

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The clear diagnosis of cirrhosis in patients caused by various reasons

Exclusion Criteria

* History of cardiovascular disease
* Diabetes
* High blood pressure
* Hepatocellular carcinoma (HCC) or other malignant tumors
* Patients with the chronic obstructive pulmonary disease
* Thyroid diseases
* Severe infection in the last 2 weeks
* History of liver transplantation and/or TIPS surgery
* Presence of stage 3 or above chronic kidney disease or acute chronic kidney disease
* Pregnant women
* Did not sign the informed consent form and refused to participate

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes